<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37643641</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>31</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1742-5662</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>205</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of the Royal Society, Interface</Title><ISOAbbreviation>J R Soc Interface</ISOAbbreviation></Journal><ArticleTitle>Medium-term scenarios of COVID-19 as a function of immune uncertainties and chronic disease.</ArticleTitle><Pagination><StartPage>20230247</StartPage><MedlinePgn>20230247</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">20230247</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1098/rsif.2023.0247</ELocationID><Abstract><AbstractText>As the SARS-CoV-2 trajectory continues, the longer-term immuno-epidemiology of COVID-19, the dynamics of Long COVID, and the impact of escape variants are important outstanding questions. We examine these remaining uncertainties with a simple modelling framework that accounts for multiple (antigenic) exposures via infection or vaccination. If immunity (to infection or Long COVID) accumulates rapidly with the valency of exposure, we find that infection levels and the burden of Long COVID are markedly reduced in the medium term. More pessimistic assumptions on host adaptive immune responses illustrate that the longer-term burden of COVID-19 may be elevated for years to come. However, we also find that these outcomes could be mitigated by the eventual introduction of a vaccine eliciting robust (i.e. durable, transmission-blocking and/or 'evolution-proof') immunity. Overall, our work stresses the wide range of future scenarios that still remain, the importance of collecting real-world epidemiological data to identify likely outcomes, and the crucial need for the development of a highly effective transmission-blocking, durable and broadly protective vaccine.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Saad-Roy</LastName><ForeName>Chadi M</ForeName><Initials>CM</Initials><Identifier Source="ORCID">0000-0002-2217-3071</Identifier><AffiliationInfo><Affiliation>Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton, NJ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Miller Institute for Basic Research in Science, University of California, Berkeley, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Integrative Biology, University of California, Berkeley, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>Sinead E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baker</LastName><ForeName>Rachel E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Brown University, Providence, RI, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute at Brown for Environment and Society, Brown University, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farrar</LastName><ForeName>Jeremy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The Wellcome Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graham</LastName><ForeName>Andrea L</ForeName><Initials>AL</Initials><Identifier Source="ORCID">0000-0002-6580-2755</Identifier><AffiliationInfo><Affiliation>Department of Ecology and Evolutionary Biology, Princeton University, Princeton, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levin</LastName><ForeName>Simon A</ForeName><Initials>SA</Initials><Identifier Source="ORCID">0000-0002-8216-5639</Identifier><AffiliationInfo><Affiliation>Department of Ecology and Evolutionary Biology, Princeton University, Princeton, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wagner</LastName><ForeName>Caroline E</ForeName><Initials>CE</Initials><Identifier Source="ORCID">0000-0001-5193-2797</Identifier><AffiliationInfo><Affiliation>Department of Bioengineering, McGill University, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Metcalf</LastName><ForeName>C Jessica E</ForeName><Initials>CJE</Initials><Identifier Source="ORCID">0000-0003-3166-7521</Identifier><AffiliationInfo><Affiliation>Department of Ecology and Evolutionary Biology, Princeton University, Princeton, NJ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Public and International Affairs, Princeton University, Princeton, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grenfell</LastName><ForeName>Bryan T</ForeName><Initials>BT</Initials><AffiliationInfo><Affiliation>Department of Ecology and Evolutionary Biology, Princeton University, Princeton, NJ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Public and International Affairs, Princeton University, Princeton, NJ, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>figshare</DataBankName><AccessionNumberList><AccessionNumber>10.6084/m9.figshare.c.6793678</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J R Soc Interface</MedlineTA><NlmUniqueID>101217269</NlmUniqueID><ISSNLinking>1742-5662</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035501" MajorTopicYN="N">Uncertainty</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">immuno-epidemiology</Keyword><Keyword MajorTopicYN="N">mathematical model</Keyword><Keyword MajorTopicYN="N">medium-term projections</Keyword></KeywordList><CoiStatement>We declare we have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>30</Day><Hour>0</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>29</Day><Hour>19</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37643641</ArticleId><ArticleId IdType="pmc">PMC10465195</ArticleId><ArticleId IdType="doi">10.1098/rsif.2023.0247</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Koelle K, Martin MA, Antia R, Lopman B, Dean NE. 2022. The changing epidemiology of SARS-CoV-2. Science 375, 1116-1121. (10.1126/science.abm4915)</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm4915</ArticleId><ArticleId IdType="pmc">PMC9009722</ArticleId><ArticleId IdType="pubmed">35271324</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden LR, et al. 2021. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403-416. (10.1056/NEJMoa2035389)</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack FP, et al. 2020. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603-2615. (10.1056/NEJMoa2034577)</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Voysey M, et al. 2021. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397, 99-111. (10.1016/S0140-6736(20)32661-1)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32661-1</ArticleId><ArticleId IdType="pmc">PMC7723445</ArticleId><ArticleId IdType="pubmed">33306989</ArticleId></ArticleIdList></Reference><Reference><Citation>King HAD, et al. 2021. Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques. Proc. Natl Acad. Sci. USA 118, e2106433118. (10.1073/pnas.2106433118)</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2106433118</ArticleId><ArticleId IdType="pmc">PMC8463842</ArticleId><ArticleId IdType="pubmed">34470866</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez DR, et al. 2021. Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice. Science 373, 991-998. (10.1126/science.abi4506)</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abi4506</ArticleId><ArticleId IdType="pmc">PMC8899822</ArticleId><ArticleId IdType="pubmed">34214046</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen AA, et al. 2022. Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models. Science 377, eabq0839. (10.1126/science.abq0839)</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abq0839</ArticleId><ArticleId IdType="pmc">PMC9273039</ArticleId><ArticleId IdType="pubmed">35857620</ArticleId></ArticleIdList></Reference><Reference><Citation>Saad-Roy CM, et al. 2020. Immune life history, vaccination, and the dynamics of SARS-CoV-2 over the next 5 years. Science 370, 811-818. (10.1126/science.abd7343)</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd7343</ArticleId><ArticleId IdType="pmc">PMC7857410</ArticleId><ArticleId IdType="pubmed">32958581</ArticleId></ArticleIdList></Reference><Reference><Citation>Saad-Roy CM, Levin SA, Metcalf CJE, Grenfell BT. 2021. Trajectory of individual immunity and vaccination required for SARS-CoV-2 community immunity: a conceptual investigation. J. R. Soc. Interface 18, 20200683. (10.1098/rsif.2020.0683)</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rsif.2020.0683</ArticleId><ArticleId IdType="pmc">PMC8086877</ArticleId><ArticleId IdType="pubmed">33530857</ArticleId></ArticleIdList></Reference><Reference><Citation>Saad-Roy CM, et al. 2021. Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes. Science 372, 363-370. (10.1126/science.abg8663)</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abg8663</ArticleId><ArticleId IdType="pmc">PMC8128287</ArticleId><ArticleId IdType="pubmed">33688062</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner CE, et al. 2021. Vaccine nationalism and the dynamics and control of SARS-CoV-2. Science 373, eabj7364. (10.1126/science.abj7364)</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abj7364</ArticleId><ArticleId IdType="pmc">PMC9835930</ArticleId><ArticleId IdType="pubmed">34404735</ArticleId></ArticleIdList></Reference><Reference><Citation>Saad-Roy CM, et al. 2021. Vaccine breakthrough and the invasion dynamics of SARS-CoV-2 variants. medRxiv. (10.1101/2021.12.13.21267725)</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.12.13.21267725</ArticleId></ArticleIdList></Reference><Reference><Citation>Saad-Roy CM, Metcalf CJE, Grenfell BT. 2022. Immuno-epidemiology and the predictability of viral evolution. Science 376, 1161-1162. (10.1126/science.abn9410)</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abn9410</ArticleId><ArticleId IdType="pubmed">35679395</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde MW, et al. 2021. Association between mRNA vaccination and COVID-19 hospitalization and disease severity. JAMA 326, 2043-2054. (10.1001/jama.2021.19499)</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.19499</ArticleId><ArticleId IdType="pmc">PMC8569602</ArticleId><ArticleId IdType="pubmed">34734975</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu-Raddad LJ, et al. 2022. Effect of mRNA vaccine boosters against SARS-CoV-2 Omicron infection in Qatar. N. Engl. J. Med. 386, 1804-1816. (10.1056/NEJMoa2200797)</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2200797</ArticleId><ArticleId IdType="pmc">PMC8929389</ArticleId><ArticleId IdType="pubmed">35263534</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirschtick JL, et al. 2021. Population-based estimates of post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC) prevalence and characteristics. Clin. Infect. Dis. 73, 2055-2064. (10.1093/cid/ciab408)</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab408</ArticleId><ArticleId IdType="pmc">PMC8240848</ArticleId><ArticleId IdType="pubmed">34007978</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelen M, et al. 2021. Characterising long COVID: a living systematic review. BMJ Global Health 6, e005427. (10.1136/bmjgh-2021-005427)</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2021-005427</ArticleId><ArticleId IdType="pmc">PMC8478580</ArticleId><ArticleId IdType="pubmed">34580069</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu E, Xie Y, Al-Aly Z. 2022. Long-term neurologic outcomes of COVID-19. Nat. Med. 28, 2406-2415. (10.1038/s41591-022-02001-z)</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02001-z</ArticleId><ArticleId IdType="pmc">PMC9671811</ArticleId><ArticleId IdType="pubmed">36138154</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonager J, et al. 2022. Molecular epidemiology of the SARS-CoV-2 variant Omicron BA.2 sub-lineage in Denmark, 29 November 2021 to 2 January 2022. Eurosurveillance 27, 2200181. (10.2807/1560-7917.ES.2022.27.10.2200181)</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2022.27.10.2200181</ArticleId><ArticleId IdType="pmc">PMC8915403</ArticleId><ArticleId IdType="pubmed">35272746</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris SE, et al. 2015. Demographic buffering: titrating the effects of birth rate and imperfect immunity on epidemic dynamics. J. R. Soc. Interface 12, 20141245. (10.1098/rsif.2014.1245)</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rsif.2014.1245</ArticleId><ArticleId IdType="pmc">PMC4345488</ArticleId><ArticleId IdType="pubmed">25589567</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker RE, Yang W, Vecchi GA, Metcalf CJE, Grenfell BT. 2020. Susceptible supply limits the role of climate in the early SARS-CoV-2 pandemic. Science 369, 315-319. (10.1126/science.abc2535)</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc2535</ArticleId><ArticleId IdType="pmc">PMC7243362</ArticleId><ArticleId IdType="pubmed">32423996</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds CJ, et al. 2022. Immune boosting by B.1.1.529 Omicron depends on previous SARS-CoV-2 exposure. Science 377, eabq1841. (10.1126/science.abq1841)</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abq1841</ArticleId><ArticleId IdType="pmc">PMC9210451</ArticleId><ArticleId IdType="pubmed">35699621</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavine JS, Bjornstad ON, Antia R. 2021. Immunological characteristics govern the transition of COVID-19 to endemicity. Science 371, 741-745. (10.1126/science.abe6522)</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abe6522</ArticleId><ArticleId IdType="pmc">PMC7932103</ArticleId><ArticleId IdType="pubmed">33436525</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies NG, et al. 2020. Age-dependent effects in the transmission and control of COVID-19 epidemics. Nat. Med. 26, 1205-1211. (10.1038/s41591-020-0962-9)</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0962-9</ArticleId><ArticleId IdType="pubmed">32546824</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun K, et al. 2021. Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2. Science 371, eabe2424. (10.1126/science.abe2424)</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abe2424</ArticleId><ArticleId IdType="pmc">PMC7857413</ArticleId><ArticleId IdType="pubmed">33234698</ArticleId></ArticleIdList></Reference><Reference><Citation>Laxminarayan R, et al. 2020. Epidemiology and transmission dynamics of COVID-19 in two Indian states. Science 370, 691-697. (10.1126/science.abd7672)</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd7672</ArticleId><ArticleId IdType="pmc">PMC7857399</ArticleId><ArticleId IdType="pubmed">33154136</ArticleId></ArticleIdList></Reference><Reference><Citation>Ndifon W, Wingreen NS, Levin SA. 2009. Differential neutralization efficiency of hemagglutinin epitopes, antibody interference, and the design of influenza vaccines. Proc. Natl Acad. Sci. USA 106, 8701-8706. (10.1073/pnas.0903427106)</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0903427106</ArticleId><ArticleId IdType="pmc">PMC2688967</ArticleId><ArticleId IdType="pubmed">19439657</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies NG, et al. 2021. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science 372, eabg3055. (10.1126/science.abg3055)</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abg3055</ArticleId><ArticleId IdType="pmc">PMC8128288</ArticleId><ArticleId IdType="pubmed">33658326</ArticleId></ArticleIdList></Reference><Reference><Citation>Merad M, Blish CA, Sallusto F, Iwasaki A. 2022. The immunology and immunopathology of COVID-19. Science 375, 1122-1127. (10.1126/science.abm8108)</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm8108</ArticleId><ArticleId IdType="pubmed">35271343</ArticleId></ArticleIdList></Reference><Reference><Citation>Mina MJ, et al. 2020. A Global lmmunological Observatory to meet a time of pandemics. eLife 9, e58989. (10.7554/eLife.58989)</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.58989</ArticleId><ArticleId IdType="pmc">PMC7292646</ArticleId><ArticleId IdType="pubmed">32510329</ArticleId></ArticleIdList></Reference><Reference><Citation>Metcalf CJE, et al. 2016. Use of serological surveys to generate key insights into the changing global landscape of infectious disease. Lancet 388, 728-730. (10.1016/S0140-6736(16)30164-7)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(16)30164-7</ArticleId><ArticleId IdType="pmc">PMC5678936</ArticleId><ArticleId IdType="pubmed">27059886</ArticleId></ArticleIdList></Reference><Reference><Citation>Metcalf CJE, Mina MJ, Winter AK, Grenfell BT. 2017. Opportunities and challenges of a World Serum Bank &#x2013; authors&#x2019; reply. Lancet 389, 252. (10.1016/S0140-6736(17)30054-5)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)30054-5</ArticleId><ArticleId IdType="pubmed">28118913</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang J, et al. 2022. Respiratory mucosal immunity against SARS-CoV-2 following mRNA vaccination. Sci. Immunol. 7, eadd4853. (10.1126/sciimmunol.add4853)</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.add4853</ArticleId><ArticleId IdType="pmc">PMC9348751</ArticleId><ArticleId IdType="pubmed">35857583</ArticleId></ArticleIdList></Reference><Reference><Citation>Topol EJ, Iwasaki A. 2022. Operation nasal vaccine&#x2014;lightning speed to counter COVID-19. Sci. Immunol. 7, 9947. (10.1126/sciimmunol.add9947)</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.add9947</ArticleId><ArticleId IdType="pubmed">35862488</ArticleId></ArticleIdList></Reference><Reference><Citation>Saad-Roy CM, Morris SE, Baker RE, Farrar J, Graham AL, Levin SA, Wagner CW, Metcalf CJE, Grenfell BT. 2023. Medium-term scenarios of COVID-19 as a function of immune uncertainties and chronic disease. Figshare. (10.6084/m9.figshare.c.6793678)</Citation><ArticleIdList><ArticleId IdType="doi">10.6084/m9.figshare.c.6793678</ArticleId><ArticleId IdType="pmc">PMC10465195</ArticleId><ArticleId IdType="pubmed">37643641</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>